Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 2 records in total 2
    records per page




    Clinical and intestinal histopathological findings in SARS-CoV-2/COVID-19 patients with hematochezia HP hematochezia MESHD

    Authors: Margaret Cho; Weiguo Liu; Sophie Balzora; Yvelisse Suarez; Deepthi Hoskoppal; Neil D Theise; Wenqing Cao; Suparna A Sarkar

    doi:10.1101/2020.07.29.20164558 Date: 2020-08-07 Source: medRxiv

    Gastrointestinal ( GI MESHD) symptoms of SARS-CoV2/COVID-19 in the form of anorexia HP anorexia MESHD, nausea, vomiting HP nausea, vomiting MESHD vomiting MESHD, abdominal pain HP abdominal pain MESHD and diarrhea HP diarrhea MESHD are usually preceeded by respiratory manifestations and are associated with a poor prognosis. Hematochezia HP Hematochezia MESHD is an uncommon clinical presentation of COVID-19 disease and we hypothesize that older patients with significant comorbidites ( obesity HP obesity MESHD and cardiovascular) and prolonged hospitalization are suspectible to ischemic injury MESHD to the bowel. We reviewed the clinical course, key laboratory data including acute phase reactants, drug/medication history in two elderly TRANS male TRANS patients admitted for COVID-19 respiratory failure HP respiratory failure MESHD. Both patients had a complicated clinical course and suffered from hematochezia HP hematochezia MESHD and acute blood SERO blood MESHD loss anemia HP requiring blood SERO transfusion around day 40 of their hospitalization. Colonoscopic impressions were correlated with the histopathological findings in the colonic biopies and changes compatible with ischemia MESHD to nonspecific acute inflammation MESHD, edema HP edema MESHD and increased eosinophils in the lamina propria were noted.Both patients were on anticoagulants, multiple antibiotics and antifungal agents due to respiratory infections MESHD at the time of lower GI bleeding MESHD. Hematochezia HP Hematochezia MESHD resolved spontaneously with supportive care. Both patients eventually recovered and were discharged. Elderly TRANS patients with significant comorbid conditions are uniquely at risk for ischemic injury MESHD to the bowel. Hypoxic conditions MESHD due to COVID-19 pneumonia HP pneumonia MESHD and respiratory failure HP respiratory failure MESHD, compounded by preexisting cardiovascular complications, and/or cytokine storm orchestrated by the viral infection leading to alteration in coagulation profile and/or drug/medication injury can be difficult to distinguish in these critically ill patients. Presentation of hematochezia HP hematochezia MESHD may further increase the mortality and morbidity of COVID-19 patients, and prompt consultation and management by gastroenterology is therefore warranted.

    Hydroxychloroquine; Why It Might Be Successful and Why It Might Not Be Successful in the Treatment of Covid-19 Pneumonia HP? Could It Be A Prophylactic Drug?

    Authors: Omer Deniz

    id:10.20944/preprints202004.0348.v3 Date: 2020-05-12 Source: Preprints.org

    According to current literature and preliminary data, hydroxychloroquine (HCQ) seems potentially effective in the treatment of patients with Covid-19 pneumonia HP pneumonia MESHD. The concentrations of HCQ in lungs might be well above that of plasma SERO. Most likely, this property of HCQ provides effective drug concentrations in lungs. HCQ has a gradual onset of action in the treatment of rheumatic diseases MESHD. This could be valid for the treatment of Covid-19 pneumonia HP pneumonia MESHD. It was suggested that regular HCQ administration in animals for a certain time might result in gradual accumulation of HCQ in tissues. Reduced perfusion, somewhat distorted architecture of lung tissue, edema HP edema MESHD and, suggested gradual accumulation of HCQ in lung tissue might cause reduced HCQ concentrations in pneumonic areas of the lungs in Covid-19 pneumonia HP pneumonia MESHD. Patients with Covid-19 pneumonia HP pneumonia MESHD and extensive lung involvement might have less HCQ concentrations in their lungs than patients having limited lung involvement. Furthermore, patients with Covid-19 pneumonia HP pneumonia MESHD and extensive lung involvement might have more viral load than patients having limited lung involvement. That’s why treatment of patients with advanced Covid-19 pneumonia HP pneumonia MESHD using HCQ might result in treatment failure, however HCQ might be effective in the treatment of patients with mild and moderate Covid-19 pneumonia HP pneumonia MESHD. Using HCQ in Covid-19 pneumonia HP pneumonia MESHD prophylaxis seems logical since providing enough accumulation of HCQ in the healthy lungs, before the arrival of the SARS-CoV-2 virus, might prevent Covid-19 pneumonia HP pneumonia MESHD. However, the purpose of this paper is not to recommend using or not using HCQ for the treatment or for the prophylaxis of Covid-19 pneumonia HP pneumonia MESHD. The purpose of this paper is only to try to bring a new perspective on the role of HCQ in the treatment or in the prophylaxis of Covid-19 pneumonia HP pneumonia MESHD. This paper proposes only hypotheses, which need further researches to be confirmed.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.